BioHarvest Sciences Inc. Common Stock Q2 2026 Earnings Call Summary

During its Q2 2026 earnings call, BioHarvest Sciences Inc. announced several key operational and strategic developments indicating a notable shift in business focus and promising growth prospects.

Securing Inaugural CDMO Contract Ahead of Schedule

BioHarvest successfully secured its first Contract Development and Manufacturing Organization (CDMO) agreement to produce a rare, high-end fragrance. This significant milestone was achieved well ahead of the originally anticipated timeline, positioning the company for streamlined revenue generation in this segment.

Strategic Pivot Towards High-Value Manufacturing and Royalties

The company is realigning its strategy by prioritizing the conversion of selected high-value opportunities into recurring manufacturing revenues and royalty streams. This includes reallocating capital and management resources away from the direct-to-consumer (D2C) segment to expand manufacturing capacity and strengthen CDMO operations.

As part of this shift, BioHarvest has reduced its D2C revenue forecast, citing a deliberate cost-containment strategy amid media cost inflation, notably on platforms such as Meta.

To improve unit economics, the company has implemented a price increase of up to 20% for new subscription customers starting with their second purchase. Management expects this price adjustment to have minimal impact on customer retention.

Leveraging Botanical Synthesis and AI-Driven Development

BioHarvest is accelerating time-to-market for strategic partners by leveraging existing molecules derived from olive, pomegranate, and blueberry within its CDMO offerings.

The company is integrating artificial intelligence and machine learning technologies into its biological development processes, supported by non-dilutive funding from the Israel Innovation Authority. This combination aims to enhance efficiency and innovation in product development.

Financial Outlook and Growth Initiatives

BioHarvest targets consolidated EBITDA breakeven by 2027 while focusing on cash flow management to avoid future equity financings. The fragrance contract is expected to generate revenue between $20 million and $30 million during 2027–2028, with limited production starting in the first half of 2027.

The CDMO division is projected to significantly reduce full-year EBITDA losses, narrowing them to a range of $1.5 million to $2.5 million by emphasizing high-value projects.

Product Expansion and Licensing Strategies

In September 2026, BioHarvest plans to launch single-dose VINIA Daily Chews aimed at engaging younger consumers and strengthening long-term loyalty.

For high-volume products such as sweeteners, the company is developing a licensing business model wherein partners construct their own manufacturing facilities while BioHarvest earns royalty revenues. This approach reduces capital expenditures and conserves cash.

Revised Revenue Guidance and Capacity Expansion

The company lowered its total 2026 revenue outlook to $37 million to $40 million from a previous estimate of $42 million to $48 million, mainly due to media cost pressures affecting the D2C business.

The fragrance contract provides BioHarvest a 20% ownership stake in business profits, with royalty terms still under negotiation. Planned capacity expansions for 2028 will be phased and funded through internally generated cash rather than upfront capital expenditures.

Operational Highlights from Q&A

  • Commercial fragrance production will begin using smaller bioreactors in early 2027, bypassing traditional large-scale Stage 3 scale-up processes.
  • Product sales revenue recognition will start in early 2027, earlier than previously planned for completion in 2028.
  • The CDMO revenue guidance was tightened to focus on high-value projects like the fragrance agreement, accelerating manufacturing and profitability milestones.
  • Partnerships with large producers such as Tate & Lyle involve partners building manufacturing facilities, with BioHarvest supplying technology licenses and earning royalties.
  • BioHarvest holds exclusive manufacturing rights for the specific fragrance raw material and anticipates a multi-year partnership.
  • The company projects approximately $180 million in revenue over five years from manufacturing this fragrance molecule.

Key Takeaways

  • BioHarvest secured its first CDMO contract ahead of schedule, signaling early commercial success.
  • The company is shifting focus from direct-to-consumer sales to high-value CDMO manufacturing and royalties.
  • Price increases and cost-containment efforts are balancing the revenue outlook in the D2C segment.
  • Strategic use of AI and existing botanical molecules aims to accelerate product development and market entry.
  • Revenue guidance revised downward due to media cost pressures, but long-term growth prospects remain positive.
  • Partnership and licensing models reduce capital expenditures and align with sustainable cash flow management.